← Back to Screener
Larimar Therapeutics, Inc. Common Stock (LRMR)
Price$3.17
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-18.38%
Price vs S&P 500 (4W)-20.14%
VGM Score37.14
Market Capitalization$329.31M
All Metrics
Book Value / Share (Quarterly)$1.52
P/TBV (Annual)1.39x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.26
Price vs S&P 500 (YTD)-24.96%
EPS (TTM)$-2.08
10-Day Avg Trading Volume1.49M
EPS Excl Extra (TTM)$-2.08
EPS (Annual)$-2.27
ROI (Annual)-212.17%
Cash / Share (Quarterly)$1.93
ROA (Last FY)-113.60%
EBITD / Share (TTM)$-2.17
ROE (5Y Avg)-82.96%
Cash Flow / Share (Annual)$-1.36
P/B Ratio2.08x
P/B Ratio (Quarterly)2.96x
Net Income / Employee (Annual)$-2,333,400
Net Interest Coverage (TTM)-248.46x
ROA (TTM)-96.00%
EPS Incl Extra (Annual)$-2.27
Current Ratio (Annual)2.19x
Quick Ratio (Quarterly)4.21x
3-Month Avg Trading Volume3.43M
52-Week Price Return28.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.11
52-Week High$6.42
EPS Excl Extra (Annual)$-2.27
CapEx CAGR (5Y)7.98%
Tangible BV CAGR (5Y)7.23%
26-Week Price Return-10.45%
Quick Ratio (Annual)2.12x
13-Week Price Return-39.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.29x
Enterprise Value$151.40M
Book Value / Share Growth (5Y)-30.60%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.65
3-Month Return Std Dev62.31%
Net Income / Employee (TTM)$-2,338,100
ROE (Last FY)-212.17%
Net Interest Coverage (Annual)-1613.25x
EPS Basic Excl Extra (Annual)$-2.27
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.08
ROI (TTM)-134.14%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.56
Price vs S&P 500 (52W)4.50%
Year-to-Date Return-16.80%
5-Day Price Return-9.69%
EPS Normalized (Annual)$-2.27
ROA (5Y Avg)-56.94%
Month-to-Date Return-8.91%
Cash Flow / Share (TTM)$-0.75
EBITD / Share (Annual)$-2.36
LT Debt / Equity (Annual)0.16x
ROI (5Y Avg)-82.96%
LT Debt / Equity (Quarterly)0.13x
EPS Basic Excl Extra (TTM)$-2.08
P/TBV (Quarterly)1.66x
P/B Ratio (Annual)4.18x
Book Value / Share (Annual)$0.94
Price vs S&P 500 (13W)-47.53%
Beta0.85x
Revenue / Share (TTM)$0.00
ROE (TTM)-134.14%
52-Week Low$2.22
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.31est. -0.55
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.47
4.47
4.47
4.44
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LRMRLarimar Therapeutics, Inc. Common Stock | — | — | D | $3.17 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using its proprietary cell-penetrating peptide technology platform. Its lead candidate, CTI-1601, is designed to deliver a critical missing protein directly to the mitochondria of patients with Friedreich's ataxia via subcutaneous injection. The company is advancing a novel treatment approach to address a significant unmet medical need in the rare disease space.